Salicylic acid
Based on 16 publication(s) in Google Scholar
Salicylic acid (2-Hydroxybenzoic acid) inhibits cyclo-oxygenase-2 (COX-2) activity independently of transcription factor (NF-κB) activation. Salicylic acid has blood-brain barrier permeability.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.23%
- CAS No.: 69-72-7
- Formule: C7H6O3
- Masse moléculaire:138.12
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-14654
AspirinCOX Inhibitor -
HY-18569
3-Indoleacetic acidPlant Growth Regulator -
HY-N0523
Gallic acidBioactive Polyhydroxyphenolic Compound -
HY-B0075
MelatoninMelatonin Receptor Activator -
HY-122464
(±)-Jasmonic acidPlant Growth Regulator -
HY-B0809
TheophyllinePDE Inhibitor -
HY-N0378
D-MannitolResistant Sugar/Osmotic Diuretics -
HY-18085
QuercetinFlavonoid Antioxidant -
HY-N1964
Gibberellic acidGrowth Regulator -
HY-B0228
AdenosineEndogenous Autacoid -
HY-100560
Abscisic acidPlant Hormone -
HY-B0272
RifampicinAntivirus Agent
Publications Citing Use of MedChemExpress (MCE) Salicylic acid
More- Nat Biomed Eng. 2026 Apr 24. [Abstract]
- Redox Biol. 2025 Feb 21:81:103561. [Abstract]
- Plant Cell. 2022 Oct 27;34(11):4641-4660. [Abstract]
- Cancer Lett. 2021 Jan 1:496:127-133. [Abstract]
- Phytomedicine. 2025 Nov 25:148:157423. [Abstract]
- Food Chem. 2023 Mar 30;405(Pt A):134807. [Abstract]
- Emerg Contam. 2026 Feb 23.
- PLoS Biol. 2024 Jun 27;22(6):e3002672. [Abstract]
- Commun Biol. 2024 Oct 18;7(1):1346. [Abstract]
- BMC Plant Biol. 2025 Jul 21;25(1):937. [Abstract]
- Clin Chim Acta. 2025 Dec 31:120816. [Abstract]
- J Orthop Surg Res. 2023 Dec 15;18(1):967. [Abstract]
- Vet Microbiol. 2026 May:316:110992. [Abstract]
- Biopharm Drug Dispos. 2022 Dec;43(6):265-271. [Abstract]
- bioRxiv. 2024 Apr 3:2023.06.02.542933. [Abstract]
- Charles University. 2020 Jul.
Voir tous les produits spécifiques à Isoform Endogenous Metabolite
More
Activité biologique
Description
IC50 & Target
[1]|
COX-2 |
Microbial Metabolite |
Autophagy |
Mitophagy |
Apoptosis |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Caco-2 | IC50 |
5 mM
Compound: salicylic acid
|
Cytotoxicity against human Caco2 cells after 24 hrs by MTT assay
Cytotoxicity against human Caco2 cells after 24 hrs by MTT assay
|
[PMID: 26617961] |
| CHO | IC50 |
280 μM
Compound: Salicylate
|
TP_TRANSPORTER: inhibition of 6-Carboxyfluorescein uptake in OAT1-expressing CHO cells
TP_TRANSPORTER: inhibition of 6-Carboxyfluorescein uptake in OAT1-expressing CHO cells
|
[PMID: 10929807] |
| DU-145 | IC50 |
>100 μM
Compound: 2; Salic
|
Antiproliferative activity against human DU-145 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human DU-145 cells incubated for 48 hrs by MTT assay
|
[PMID: 36257283] |
| HEK293 | IC50 |
>15 mM
Compound: Salicylate
|
Cytotoxicity against HEK293 cells harboring pendrin P123S mutant after 72 hrs by MTT assay
Cytotoxicity against HEK293 cells harboring pendrin P123S mutant after 72 hrs by MTT assay
|
[PMID: 28341401] |
| HT-29 | IC50 |
>100 μM
Compound: 2; Salic
|
Antiproliferative activity against human HT-29 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human HT-29 cells incubated for 48 hrs by MTT assay
|
[PMID: 36257283] |
| MCF7 | IC50 |
>100 μM
Compound: 2; Salic
|
Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay
|
[PMID: 36257283] |
| MDCK | EC50 |
>250 μM
Compound: 22
|
Plaque growth inhibition
Plaque growth inhibition
|
[PMID: 22211528] |
| RAW264.7 | CC50 |
>40 μM
Compound: 1
|
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in survival rate after 24 hrs by MTT assay
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in survival rate after 24 hrs by MTT assay
|
[PMID: 25200306] |
| Sf21 | IC50 |
>1000 μM
Compound: Salicylic acid
|
Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
|
[PMID: 21965623] |
| Sf21 | IC50 |
>1000 μM
Compound: Salicylic acid
|
Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
|
[PMID: 21965623] |
| Sf9 | IC50 |
500 μM
Compound: salicylic acid
|
Inhibition of human recombinant COX1 expressed in Sf9 cell microsomes assessed as reduction in conversion of arachidonic acid to PGE2 incubated for 5 mins by HTRF assay
Inhibition of human recombinant COX1 expressed in Sf9 cell microsomes assessed as reduction in conversion of arachidonic acid to PGE2 incubated for 5 mins by HTRF assay
|
[PMID: 27046190] |
In Vitro
Salicylic acid is an effective inhibitor of COX-2 activity at concentrations far below those required to inhibit NF-κB (20 mg/mL) activation. Salicylic acid inhibits prostaglandin E2 release when add together with interleukin 1β for 24 hr with an IC50 value of 5 μg/mL, an effect that is independent of NF-κB activation or COX-2 transcription or translation. Salicylic acid acutely (30 min) also causes a concentration-dependent inhibition of COX-2 activity measured in the presence of 0, 1, or 10 μM exogenous arachidonic acid. In contrast, when exogenous arachidonic acid is increased to 30 μM, Salicylic acid is a very weak inhibitor of COX-2 activity with an IC50 of >100 μg/mL. When added together with IL-1β for 24 hr, Salicylic acid causes a concentration-dependent inhibition of PGE2 release with an apparent IC50 value of approximately 5 μg/mL. The ability of Salicylic acid to directly inhibit COX-2 activity in A549 cells is tested after a 30-min exposure period, followed by the addition of different concentrations of exogenous arachidonic acid (1, 10, and 30 μM). Salicylic acid causes a concentration-dependent inhibition of COX-2 activity in the absence of added arachidonic acid or in the presence of 1 or 10 μM exogenous substrate with an apparent IC50 value of approximately 5 μg/mL. However, when the same experiments are performed using 30 μM arachidonic acid, Salicylic acid is an ineffective inhibitor of COX-2 activity, with an apparent IC50 value of more than 100 μg/mL, and achieves a maximal inhibition of less than 50%[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 69-72-7
-
Appearance Solid
-
Masse moléculaire 138.12
-
Formule C7H6O3
-
Color Off-white to light brown
-
SMILES
O=C(O)C1=CC=CC=C1O
-
Synonyms
2-Hydroxybenzoic acid
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (16)
-
Journal Impact Factor
-
Most Recent
-
Nat Biomed Eng
DeepDrugDiscovery identifies blood-brain barrier permeable autophagy enhancers for Alzheimer's disease. [Abstract]2026 Apr 24. PMID: 42032039 -
Redox Biol
2025 Feb 21:81:103561. PMID: 40020452 -
Plant Cell
AIG2A and AIG2B limit the activation of salicylic acid-regulated defenses by tryptophan-derived secondary metabolism in Arabidopsis. [Abstract]2022 Oct 27;34(11):4641-4660. PMID: 35972413 -
Cancer Lett
Palmitic acid negatively regulates tumor suppressor PTEN through T366 phosphorylation and protein degradation. [Abstract]2021 Jan 1:496:127-133. PMID: 33039560 -
Phytomedicine
Arnicolide C induces ROS-mediated modulation of PI3K/Akt and MAPK pathways to suppress MYC in hepatocellular carcinoma. [Abstract]2025 Nov 25:148:157423. PMID: 41138574 -
Food Chem
Discovery of novel ascorbic acid derivatives and other metabolites in fruit of Rosa roxburghii Tratt through untargeted metabolomics and feature-based molecular networking. [Abstract]2023 Mar 30;405(Pt A):134807. PMID: 36370576 -
-
PLoS Biol
2024 Jun 27;22(6):e3002672. PMID: 38935621 -
Commun Biol
Thalamo-cortical neural mechanism of sodium salicylate-induced hyperacusis and anxiety-like behaviors. [Abstract]2024 Oct 18;7(1):1346. PMID: 39420035 -
BMC Plant Biol
Comparative transcriptome analysis reveals key genes and signaling pathways mediated by salicylic acid in potato. [Abstract]2025 Jul 21;25(1):937. PMID: 40691758 -
Clin Chim Acta
Simultaneous quantification of acetylsalicylic acid, clopidogrel, ticagrelor and their major metabolites in human plasma by liquid chromatography-tandem mass spectrometry. [Abstract]2025 Dec 31:120816. PMID: 41482259 -
J Orthop Surg Res
Sodium salicylate ameliorates exercise-induced muscle damage in mice by inhibiting NF-kB signaling. [Abstract]2023 Dec 15;18(1):967. PMID: 38098039 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607 -
Biopharm Drug Dispos
Inhibition of canalicular and sinusoidal taurocholate efflux by cholestatic drugs in human hepatoma HepaRG cells. [Abstract]2022 Dec;43(6):265-271. PMID: 36195987 -
bioRxiv
An efficient behavioral screening platform classifies natural products and other chemical cues according to their chemosensory valence in C. elegans. [Abstract]2024 Apr 3:2023.06.02.542933. PMID: 37333363 -
Solvant et solubilité
In Vitro:
DMSO : ≥ 50 mg/mL (362.00 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 1 mg/mL (7.24 mM; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (18.10 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (18.10 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (284 KB)
-
SDS (779 KB)
- English - EN (779 KB)
- Français - FR (779 KB)
- Deutsch - DE (779 KB)
- Norwegian - NO (779 KB)
- Español - ES (779 KB)
- Swedish - SV (779 KB)
- Italian - IT (779 KB)
- Korean - KR (779 KB)
- Portuguese - PT (779 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Mitchell JA, et al. Sodium salicylate inhibits cyclo-oxygenase-2 activity independently of transcription factor (nuclear factor kappaB) activation: role of arachidonic acid. Mol Pharmacol. 1997 Jun;51(6):907-12. [Content Brief]
[2]. Nixon M, et al. Salicylate downregulates 11β-HSD1 expression in adipose tissue in obese mice and in humans, mediating insulin sensitization. Diabetes. 2012 Apr;61(4):790-6. [Content Brief]
[3]. Kang YS, et al. Acidic drug transport in vivo through the blood-brain barrier. A role of the transport carrier for monocarboxylic acids. J Pharmacobiodyn. 1990 Feb;13(2):158-63. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 7.2401 mL | 36.2004 mL | 72.4008 mL | 181.0020 mL |
| 5 mM | 1.4480 mL | 7.2401 mL | 14.4802 mL | 36.2004 mL | |
| DMSO | 10 mM | 0.7240 mL | 3.6200 mL | 7.2401 mL | 18.1002 mL |
| 15 mM | 0.4827 mL | 2.4134 mL | 4.8267 mL | 12.0668 mL | |
| 20 mM | 0.3620 mL | 1.8100 mL | 3.6200 mL | 9.0501 mL | |
| 25 mM | 0.2896 mL | 1.4480 mL | 2.8960 mL | 7.2401 mL | |
| 30 mM | 0.2413 mL | 1.2067 mL | 2.4134 mL | 6.0334 mL | |
| 40 mM | 0.1810 mL | 0.9050 mL | 1.8100 mL | 4.5251 mL | |
| 50 mM | 0.1448 mL | 0.7240 mL | 1.4480 mL | 3.6200 mL | |
| 60 mM | 0.1207 mL | 0.6033 mL | 1.2067 mL | 3.0167 mL | |
| 80 mM | 0.0905 mL | 0.4525 mL | 0.9050 mL | 2.2625 mL | |
| 100 mM | 0.0724 mL | 0.3620 mL | 0.7240 mL | 1.8100 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Salicylic acid Related Classifications
HY-B0167 Related Classifications
Powered by Bioz